BioNTech (BNTX.US) stock erased early losses and rose over 1.0% on Monday even despite the fact that the biotechnology company reported a 43% decline in Q3 sales from a year ago and 44% fall in net profit.
-
Diluted earnings per share in the third quarter amounted to €6.98,
-
Net profit came to €1.78 billion, down from €3.21 billion in the same period in 2021. Nevertheless both metrics topped FactSet analysts’ estimates.
-
Operating income came in at €2.38 billion, which is a 49% decline compared to last year.
-
"Thanks to our strong execution in the third quarter of 2022, we updated our COVID-19 vaccine revenue guidance for the year 2022 to the upper end of the original range," said CFO Jens Holstein.
-
Company now expects full-year Covid-vaccine revenue of €16 billion-€17 billion ($16 billion-$17 billion), from €13 billion-€17 billion previously.
-
Drugmaker revealed that approximately 300 million doses of it and Pfizer’s bivalent vaccine had been invoiced as of mid-October.
-
Nevertheless a lot will depend on booster demand. Recent data from Centers for Disease Control and Prevention showed that less than 10% of adults in the US have gotten an updated booster shot. Among people who turned 65 years, less than one quarter received a booster shoot.
BioNTech (BNTX.US) stock rose sharply last week following the news that China approved BioNTech’s Covid-19 vaccines for foreign residents. Positive sentiment prevails today, and as long as price sits above the 200 SMA (red line), another upward impulse may be launched towards major resistance at $184.70, which is marked with previous price reactions. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
